GlassScriptPhysician profile
Matthew Lobosco
NPI 1487896148
$2,591.27
in general payments reported to CMS, 2019-2025
19 companies · $2,116 in 2025
The $2,116 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.07 · 2024: $456 · 2025: $2,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,349.22 |
| Education | $222.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $606.99 | 2025 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $473.66 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $412.53 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $178.93 | 2024-2025 | Lybalvi, Vivitrol |
| Abbvie INC. | $141.72 | 2024-2025 | |
| Almatica Pharma LLC | $136.88 | 2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $115.47 | 2024-2025 | Fanapt |
| Biogen, INC. | $86.93 | 2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $82.64 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $57.29 | 2024-2025 | Spravato |
| Luye Pharma (USA) LTD. | $48.33 | 2025 | Erzofri Extended-Release |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.72 | 2024-2025 | Caplyta |
| Bausch Health US, LLC | $44.98 | 2025 | Aplenzin |
| Braeburn INC. | $40.26 | 2024-2025 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $32.94 | 2025 | Trintellix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $29.34 | 2025 | Azstarys |
| Axsome Therapeutics, INC. | $21.26 | 2025 | Auvelity |
| Lilly USA, LLC | $19.07 | 2020 | |
| Neurocrine Biosciences, INC. | $15.33 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lobosco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.